The introduction of GLEEVEC® (imatinib mesylate) tablets revolutionized treatment for Philadelphia chromosome-positive chronic myeloid leukemia (Ph+ CML). (Click here for important GLEEVEC safety information and full Prescribing Information.)
A small percentage of Ph+ CML patients who take GLEEVEC either fail to respond to treatment or lose their response over time. When this happens, it is called drug resistance.
Researchers continue to investigate why some patients never respond well to GLEEVEC. However, they have a good understanding of why some people lose their response—even after years of successful treatment.
What causes resistance?
Over time the Bcr-Abl protein, the signal that tells your body to produce too many white blood cells, can change or mutate. When this happens, GLEEVEC can stop working as well as it used to. When GLEEVEC is unable to keep the Bcr-Abl protein in check, the signal turns on again and your body starts making too many damaged white blood cells.
How does your doctor know if you are resistant?
Your doctor determines whether or not you are resistant to GLEEVEC by watching over time to see if you are meeting your treatment goals. This is done by monitoring your response to treatment using blood and bone marrow tests. If you fail to meet your treatment goals, or you stop responding well to treatment, you may be resistant to GLEEVEC. Resistance is often defined by the measurements below:
Take TASIGNA 150-mg or 200-mg capsules as prescribed
Even when tests show you are responding to TASIGNA, you may have levels of the Bcr-Abl protein in your blood and bone marrow that are not detectable by blood and bone marrow tests. If you stop taking your TASIGNA or don't take it exactly as prescribed, the signal that leads your body to produce too many white blood cells could be activated again. Work closely with your doctor to monitor your progress. It is important that you don't change the amount of TASIGNA you take or stop taking it without talking to your doctor first. Ongoing monitoring, even when you are responding well, can help you and your doctor treat your condition.
Find More Information
QT prolongation causes an irregular heartbeat, which may lead to sudden death.
Your doctor should check your heart with a test called an electrocardiogram (ECG):
TASIGNA® (nilotinib) Indications
TASIGNA is a prescription medicine used to treat adults with newly diagnosed Philadelphia chromosome–positive chronic myeloid leukemia (Ph+ CML) in chronic phase. The efficacy of TASIGNA is based on major molecular response and cytogenetic response rates. The study is on-going and more data will be needed to determine long-term outcomes.
TASIGNA is also used to treat chronic phase or accelerated phase Philadelphia chromosome–positive chronic myeloid leukemia (Ph+ CML) in adults who are no longer benefiting from previous other treatments, including imatinib (GLEEVEC), or have taken other treatments, including imatinib (GLEEVEC) but cannot tolerate them. The efficacy of TASIGNA is based on hematologic response and cytogenetic response rates.
IMPORTANT SAFETY INFORMATION ABOUT TASIGNA® (nilotinib)
What is the most important information to know about prescription TASIGNA?
TASIGNA can cause a possible life-threatening heart problem called QT prolongation.
QT prolongation causes an irregular heartbeat, which may lead to sudden death.
Your doctor should check your heart with a test called an electrocardiogram (ECG):
You may lower your chances for having QT prolongation with TASIGNA if you:
Who should not take TASIGNA?
Do not take if you have:
Taking TASIGNA:
Before taking TASIGNA
Talk to your doctor or pharmacist about all other medication(s) you may be taking, including prescription medicines, over-the-counter medicines, vitamins, and herbal supplements, since they may affect how TASIGNA works and increase your chance of serious and life-threatening side effects.
Tell your doctor if:
Also tell your doctor if you are pregnant, breast-feeding, or lactose-intolerant. The TASIGNA capsules contain lactose. Most patients who have mild or moderate lactose intolerance can take TASIGNA.
Serious side effects
TASIGNA may cause serious side effects including:
Your doctor may do blood tests to check you for TLS
Call your doctor immediately if you experience any of these symptoms. Your doctor may change your dose. Your doctor may have you stop TASIGNA for some time or lower your dose if you have side effects with it.
Common side effects
Most patients experience side effects at some time. Some common side effects you may experience include:
Be sure to tell your doctor or pharmacist if you have any side effects during treatment with TASIGNA. You are encouraged to report side effects of prescription drugs to the FDA. Visit www.fda.gov/medwatch, or call 1-800-FDA-1088.
It is not known if TASIGNA is safe or effective in children.
Tell your doctor if you are pregnant or planning to become pregnant. TASIGNA may harm your unborn baby. If you are able to become pregnant, you should use effective birth control during treatment with TASIGNA. Talk to your doctor about the best birth control methods to prevent pregnancy while you are taking TASIGNA.
Tell your doctor if you are breast-feeding or plan to breast-feed. It is not known if TASIGNA passes into your breast milk. You and your doctor should decide if you will take TASIGNA or breast-feed. You should not do both.
If you take too much TASIGNA, call your doctor or poison control center right away.
Your doctor will check your heart, do regular blood tests, and take bone marrow samples during treatment with TASIGNA. These are done to check for side effects with TASIGNA and to see how well TASIGNA is working for you. Your doctor should check your blood to monitor the amount of blood cells (white blood cells, red blood cells, and platelets) during treatment. These should be checked every 2 weeks for the first 2 months and then monthly thereafter, or as considered necessary by your doctor.
Please see the full prescribing information including the Boxed WARNING, and the TASIGNA Medication Guide.